Abstract
Staphylococci are among the leading causes of nosocomial infections. Increasing insusceptibility to β-lactams and the glycopeptides complicates treatment of these infections. This review examines the current status and future perspectives for the therapy of infections caused by Staphylococcus aureus and coagulase-negative staphylococci. © 2007 Elsevier B.V. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | S23-S32 |
| Journal | International Journal of Antimicrobial Agents |
| Volume | 29 |
| Issue number | Suppl. 3 |
| DOIs | |
| Publication status | Published - May 2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- antibiotics
- antimicrobial resistance
- coagulase-negative staphylococci
- staphylococcus aureus
Fingerprint
Dive into the research topics of 'Staphylococci'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver